Specialist Updates 
Cardiology

Finerenone cuts CV risk in patients with diabetes and kidney disease

The new agent reduces hospitalisation for heart failure and renal disease progression, research shows
Medicom
0
3 September 2021
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.

The first-in-class non-steroidal mineralocorticoid receptor antagonist finerenone improves cardiovascular outcomes in patients with type 2 diabetes and early-stage kidney disease, a major trial shows.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .